Evidence mapPaperPMID 42444907Full record

ArticleJournal of thoracic disease2026

A bibliometric analysis of lung cancer and atrial fibrillation [1991-2026]: research hotspots, thematic evolution, and translational landscape in cardio-oncology.

Zongrong Lin, Sicheng Chen, Yang Liu, Hongcheng Chen, Yining Dai, Haomin Xie, Wenliang Wang, Daofu Huang, Zhenyang Fu

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zongrong Lin *Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, The First Clinical Medical School of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China.
Sicheng Chen *Department of Cardiovascular Disease, Shantou Hospital of Traditional Chinese Medicine, Shantou, China.
Yang Liu *Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, The First Clinical Medical School of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China.
Hongcheng Chen *Department of Gastroenterology, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Yining Dai *Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Haomin XieDepartment of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, The First Clinical Medical School of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China.
Wenliang WangDepartment of Cardiovascular Disease, Shantou Hospital of Traditional Chinese Medicine, Shantou, China.
Daofu Huang *Department of Thoracic Surgery, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Zhenyang Fu *Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, The First Clinical Medical School of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The intersection of lung cancer (LC) and atrial fibrillation (AF) is common in thoracic surgery, systemic cancer therapies, and cardio-oncology, yet the research landscape remains inadequately characterized. To understand the progression of LC-AF research, a detailed overview is necessary to identify its main research focuses and highlight the most pertinent knowledge gaps for upcoming clinical and translational research. The present study aimed to systematically clarify the global research landscape, translational priorities, and key molecular signatures relevant to contemporary clinical and scientific focus in LC-AF comorbidity via a multi-perspective approach. Methods: We conducted a bibliometric study on LC-AF literature sourced from the SCI-Expanded database in the Web of Science Core Collection (WoSCC), updated to April 2026, including original articles and reviews after a predefined screening process. Clinical trial records indexed in PubMed were analyzed as an additional module to explore trends in trial-oriented clinical trends. Additionally, a transcriptomic analysis that integrates AF and LC datasets was carried out to give molecular context to repeated bibliometric themes. Results: The LC-AF field experienced steady publication growth, which became more pronounced post-2015. The primary contributors were the United States and China, with productive institutions clustered in several renowned global academic centers. Research hotspots were mainly centered on perioperative AF, thoracic surgery, cardiovascular complications, and risk-factor assessment, with thematic evolution toward cardio-oncology, treatment-related toxicity, immunotherapy, and precision-oriented research. Supplementary analysis of trials pointed to a need for greater emphasis on precision therapy, age-specific management, and more rigorous study designs. The transcriptomic exploratory study pinpointed shared genes with differential expression, including Conclusions: The field of LC-AF research is expanding from a focus on perioperative and descriptive aspects to include a wider cardio-oncology orientation. Future work should prioritize long-term follow-up in comorbid populations, clearer distinction between perioperative and chronic AF scenarios, prospective multicenter validation of risk models, and translational studies linking molecular signals to perioperative surveillance and treatment decision-making.

Indexed as

atrial fibrillation (AF)bibliometric analysiscardio-oncologyLung cancer (LC)perioperative atrial fibrillation (POAF)

Identifiers

PMID42444907
PMCPMC13358482

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.